Status:
COMPLETED
A Study of LY2835219 in Healthy Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy Volunteers
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The aim of this two-period study is to compare how much of the study drug gets into the blood stream when it is given as a single oral dose and when it is given as a single oral dose in combination wi...
Eligibility Criteria
Inclusion
- Overtly healthy sterile males or surgically sterile females or postmenopausal females
- Have a body mass index (BMI) of 18 to 32 kilogram per meter square (kg/m\^2)
Exclusion
- Have participated in a clinical trial involving investigational product within the last 30 days
- Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
- Have an abnormal blood pressure
- Show evidence of human immunodeficiency virus (HIV), hepatitis B or hepatitis C
- Have donated blood of more than 500 milliliters (mL) within the last month
- Have used or intend to use over-the-counter or prescription medication including herbal medications within 7 days prior to dosing or during the study
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2014
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT02256267
Start Date
October 1 2014
End Date
November 1 2014
Last Update
January 7 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Dallas, Texas, United States, 75247